Mazucanti Caio Henrique, Egan Josephine Mary
National Institute on Aging, Intramural Research Program, 251 Bayview Boulevard, Baltimore, MD 21224 USA.
Immun Ageing. 2020 Jun 30;17:21. doi: 10.1186/s12979-020-00192-y. eCollection 2020.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic, has infected over 3.5 million people all over the world since the first case was reported from Wuhan, China 5 months ago. As more epidemiological data regarding COVID-19 patients is acquired, factors that increase the severity of the infection are being identified and reported. One of the most consistent co-morbidities associated with worse outcome in COVID-19 patients is diabetes, along with age and cardiovascular disease. Studies on the association of diabetes with other acute respiratory infections, namely SARS, MERS, and Influenza, outline what seems to be an underlying factor in diabetic patients that makes them more susceptible to complications. In this review we summarize what we think may be the factors driving this pattern between diabetes, aging and poor outcomes in respiratory infections. We also review therapeutic considerations and strategies for treatment of COVID-19 in diabetic patients, and how the additional challenge of this co-morbidity requires attention to glucose homeostasis so as to achieve the best outcomes possible for patients.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是引发当前2019冠状病毒病（COVID-19）大流行的一种新型病毒。自5个月前中国武汉报告首例病例以来，全球已有超过350万人感染。随着获得越来越多关于COVID-19患者的流行病学数据，导致感染严重程度增加的因素正在被识别和报道。与COVID-19患者预后较差最一致的合并症之一是糖尿病，还有年龄和心血管疾病。关于糖尿病与其他急性呼吸道感染（即SARS、中东呼吸综合征和流感）关联的研究，概述了糖尿病患者中似乎存在的一个潜在因素，即他们更容易出现并发症。在本综述中，我们总结了我们认为可能是导致糖尿病、衰老与呼吸道感染不良预后之间这种模式的因素。我们还回顾了糖尿病患者COVID-19治疗的相关考量和策略，以及这种合并症带来的额外挑战如何需要关注葡萄糖稳态，以便为患者实现尽可能最佳的治疗效果。
